Atara Biotherapeutics (ATRA)
Supports Pierre Fabre’s global EBV-targeted tab-cel program through a lean partner-led operating model.
$8.47
vs last close−0.46 (−5.15%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 49 days
EPS estimate
−$0.13
Revenue estimate
$800.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.19$3.50$0.19−$0.32−$0.25−$0.29−$0.32Pending
Estimate−$3.82−$3.07−$0.32−$0.83−$0.09−$0.33−$0.32−$0.13
Surprise+68.8%+214.0%+159.4%+61.4%−177.8%+12.0%−1.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$32.8M$98.1M$17.6M$3.5M$1.6M$516.0K$630.0KPending
Estimate$20.6M$4.3M$1.8M$700.0K$3.4M$2.9M$550.0K$800.0K
Surprise+59.1%+2,182.5%+876.4%+393.3%−51.2%−82.2%+14.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Jun 2027 | $1.00 | — | — |
| Mar 2027 | −$0.17 | — | — |
| Dec 2026 | −$0.09 | — | — |
| Nov 2026 | −$0.13 | — | — |
| Aug 2026 | −$0.32 | −$0.32 | −1.6% |
| May 2026 | −$0.33 | −$0.29 | +12.0% |
| Mar 2026 | −$0.09 | −$0.25 | −177.8% |
| Nov 2025 | −$0.83 | −$0.32 | +61.4% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Jun 2027 | $1.00 | — | — | $31.7M | — | — | — |
| Mar 2027 | −$0.17 | — | — | $100.0K | — | — | — |
| Dec 2026 | −$0.09 | — | — | $1.4M | — | — | — |
| Nov 11, 2026 | −$0.13 | — | — | $800.0K | — | — | — |
| Aug 12, 2026 | −$0.32 | −$0.32 | −1.6% | $550.0K | $630.0K | +14.5% | −7.8% |
| May 14, 2026 | −$0.33 | −$0.29 | +12.0% | $2.9M | $516.0K | −82.2% | −8.5% |
| Mar 16, 2026 | −$0.09 | −$0.25 | −177.8% | $3.4M | $1.6M | −51.2% | −9.7% |
| Nov 12, 2025 | −$0.83 | −$0.32 | +61.4% | $700.0K | $3.5M | +393.3% | −0.7% |
| Aug 11, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 7, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 8, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 4, 2021 | |||||||
| Mar 1, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 27, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 9, 2017 | |||||||
| Nov 4, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 5, 2016 | |||||||
| Mar 3, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 6, 2015 |